Share tips of the week
MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
Six to buy
Byotrol
(The Mail on Sunday) Hand sanitiser is “flying off the shelves”, but regulation about what is in the products remains surprisingly lax: many are only effective for a short time and often use alcohol, which can irritate sensitive skin. This “fast-growing” Aim business offers antimicrobial products “backed by rigorous scientific research” and boasts strong commercial links with the likes of Boots and the NHS. Three positive trading updates in recent months suggest the “best is yet to come”. 6p
B&M European Value Retail
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
(Investors Chronicle) This discount retailer sells groceries, kitchenware and furniture through its 656 UK stores. More consumers than ever are shopping at discounters and lockdown has brought new shoppers through the doors. Once they start using B&M, customers tend to remain loyal, with 82% reporting that they shop there “regularly or occasionally”. The group’s shares are popular with money managers and, trading on 16 times forecast earnings, the valuation is reasonable. 486p
Clinigen
(The Sunday Telegraph) Big pharmaceutical firms are in fashion. This stock offers a way to “co-operate” rather than “compete” with the industry giants. Clinigen supplies the drugs used for clinical trials, a highly regulated area that requires careful compliance. The group also makes money sourcing as yet unlicensed medicines and also invests in drug licences when it spots an opportunity others have missed. Clinigen is not big pharma, but “it is big enough to prosper”. On 11.3 times forecast earnings the shares are a buy. 694p
Spirent
(Shares) This multinational telecommunications testing business is at the forefront of the rollout of 5G mobile networks. 5G should deliver much faster mobile download speeds and bigger bandwidth, satisfying the economy’s insatiable appetite for data. Investment in the technology continued through the Covid-19 crisis, a testament to the “mission-critical” nature of Spirent’s work for military and scientific organisations. The firm has been on a “hiring binge” to keep up with customer demand. On a forward price/earnings ratio of 25, the stock should be tucked away for the medium to long term. 301p
Merck
(Barron’s) The healthcare rally has passed this American pharma business by, with the shares down by 8% for the year to date. The market is concerned about Merck’s dependence on Keytruda, a blockbuster cancer drug that accounts for about 30% of revenue, but whose patent expires in 2028. Nevertheless, Merck has time to launch new treatments before then and its vaccine division is working on two potential Covid-19 vaccines. With a secure 3% dividend yield and trading on an undemanding 15 times this year’s earnings, the shares offer exposure to a top-class pharmaceutical player “at a reasonable price”. $83
Topps Tiles
(The Times) Housebound DIY enthusiasts appear to be driving a revenue rebound at this tiling retailer, which is considered something of a “barometer of consumer confidence”. Sales remain down compared with this time last year, but a recovery is under way, leading to hopes that Topps will manage to turn a profit this year after all. CEO Rob Parker notes that customers are using YouTube videos to prepare themselves for more ambitious home-improvement projects than in the past. The group will not pay a dividend this year as it used government help during the lockdown, but payouts should resume in 2021. Buy. 49p
... and the rest
The Daily Telegraph
Uranium oxide supplier Yellow Cake stands to gain from a shortage of the nuclear fuel. A buy for the risk-tolerant “contrarian” (213p).
Investors Chronicle
Mature natural gas-field investor Diversified Gas & Oil proved its resilience in the first half and pays a 10%+ dividend (100p). These are grim times for commercial landlords, but Helical’s prime London and Manchester portfolio and robust balance sheet bode well. Buy (310p). Gym closures have driven new interest in solo exercise. That promises new business for US tech firm Garmin, which specialises in exercise tracking gadgets. Buy ($102).
The Mail on Sunday
Shares in video-games developer Codemasters, best known for its racing games, are up by 40% since January thanks to a surge in demand during lockdown. Take some profits (395p).
Shares
Higher audience figures during lockdown have not delivered an advertising-income jump for ITV, but “we are keeping the faith” (64p). Shares in Trinidad oil play Touchstone Exploration are up by 40% since June and rising production could keep the positive momentum going (73p).
The Times
Balfour Beatty should be one of the big winners from Boris Johnson’s Keynesian “infrastructure splurge”. On about 11 times forward earnings the shares are reasonably priced (258p). BP’s new green strategy is a good start, but it remains to be seen whether it succeeds in new renewables markets, such as offshore wind, where competition is already intense. Hold (299p).
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Will UK inflation rise ahead of BoE meeting?
August’s inflation report will be published at 7am on Wednesday, 17 September, one day before the Bank of England’s next rate-setting meeting
-
Thousands of savers with £250k pensions take cash over tax-free money and IHT fears
With a record £70 billion withdrawn from pensions in the year to March, experts are concerned savers are making knee-jerk decisions without advice that could affect their long term wealth
-
Small UK industrial stocks are hidden gems
Opinion Ed Wielechowski of the Odyssean Investment Trust highlights three of his favourite British small-cap industrial stocks
-
Aurora Innovation is running on empty – is it overvalued?
Aurora Innovation, a maker of self-driving trucks, may have promised far more than it can deliver
-
'Ride the recovery in emerging markets': Gustavo Medeiros of Ashmore Group tells MoneyWeek
Interview What's the outlook for emerging markets? Gustavo Medeiros, head of research at Ashmore Group, gives his analysis and reviews progress in developing economies
-
What is the Enterprise Investment Scheme and should you have one?
The Enterprise Investment Scheme is tax-efficient and potentially lucrative. Taking a chance on the scheme could trim your family’s IHT bill, says David Prosser
-
The alcohol industry is suffering as consumers sober up – is it still worth investing in the sector?
Changing consumer tastes are rocking the alcohol industry, but the best players are adapting their strategies. Buy them while their shares are still cheap
-
A strange calm in credit
Corporate bond markets remain remarkably relaxed, with yields that offer little compensation for risks
-
'The City's big bet on green finance fails to pay out'
Opinion Insurers and banks are backing away from “green finance”, and there is not much sign of the green boom we were promised. That’s a problem for the City
-
Six top investment trusts for smaller stocks
Liquidity constraints mean investment trusts are best placed to seize the juiciest opportunities